HF
AMLX icon

HRT Financial’s Amylyx Pharmaceuticals AMLX Stock Holding History

HRT Financial’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-127,998
Closed -$453K – 2544
2025
Q1 		$453K Buy
+127,998
New +$456K ﹤0.01% 1519
2024
Q4 		– Sell
-81,291
Closed -$263K – 2385
2024
Q3 		$263K Buy
81,291
+51,748
+175% +$116K ﹤0.01% 1857
2024
Q2 		$56K Buy
+29,543
New +$57.3K ﹤0.01% 1821
2024
Q1 		– Sell
-42,192
Closed -$621K – 2258
2023
Q4 		$621K Buy
42,192
+16,098
+62% +$247K ﹤0.01% 1248
2023
Q3 		$477K Sell
26,094
-23,112
-47% -$489K ﹤0.01% 1427
2023
Q2 		$1.06M Sell
49,206
-44,584
-48% -$1.2M 0.01% 918
2023
Q1 		$2.75M Buy
+93,790
New +$3.26M 0.03% 457

Other funds holding AMLX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

HRT Financial's AMLX Position: Q2 2025 in Review

HRT Financial sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2025, closing a stake of 127,998 shares — an estimated $453K sold.

HRT Financial first reported a position in AMLX in Q1 2023 and held it in 7 quarters. The position peaked at $2.75M in Q1 2023. 131 funds tracked by Wall St. Rank hold AMLX as of Q2 2025.

  • HRT Financial reported no remaining Amylyx Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • HRT Financial sold 127,998 Amylyx Pharmaceuticals shares in Q2 2025, an estimated $453K.
  • HRT Financial first reported a position in Amylyx Pharmaceuticals in Q1 2023 and held it in 7 quarters.
  • HRT Financial's Amylyx Pharmaceuticals position peaked at $2.75M in Q1 2023.
  • 131 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.